Which cancers can cause paraneoplastic Syndrome of Inappropriate Antidiuretic Hormone (SIADH)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 1, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Cancers That Cause Paraneoplastic SIADH

Small cell lung cancer (SCLC) is the predominant malignancy causing paraneoplastic SIADH, accounting for the vast majority of cases, while non-small cell lung cancer and other malignancies cause SIADH much less frequently. 1

Primary Malignancies Associated with SIADH

Lung Cancer (Most Common)

Small Cell Lung Cancer (SCLC)

  • SCLC is by far the most common cancer causing paraneoplastic SIADH, with 10-45% of SCLC cases producing arginine vasopressin (ADH), though only 1-5% develop symptomatic SIADH 1
  • SCLC cells have neuroendocrine features that enable ectopic ADH production, making this the most frequent endocrine paraneoplastic syndrome in SCLC 2
  • Biochemical evidence of elevated ADH is present in approximately 38% of SCLC patients, even when clinically asymptomatic 3
  • The hyponatremia associated with SCLC-related SIADH is linked to shortened survival 1

Non-Small Cell Lung Cancer (NSCLC)

  • NSCLC causes paraneoplastic SIADH in only approximately 1% of cases, making it significantly less common than SCLC 1, 2
  • Both squamous cell carcinoma and adenocarcinoma subtypes of NSCLC have been reported to cause SIADH, though this remains rare 1, 4

Hematologic Malignancies

Myelodysplastic Syndrome

  • Myelodysplastic syndrome with blast crisis has been documented to cause SIADH, though this is an uncommon association 5
  • In these patients, SIADH should be considered in the differential diagnosis of hyponatremia 5

Clinical Significance and Management Implications

Recognition of the underlying malignancy is critical because treatment of the cancer is the definitive therapy for paraneoplastic SIADH 1, 2

  • Hyponatremia typically improves after successful treatment of the underlying SCLC with chemotherapy 2
  • Early detection and appropriate management can prevent severe hyponatremia leading to seizures, coma, and death 1
  • In SCLC patients, the presence of SIADH may serve as a tumor marker, with plasma ADH levels potentially useful for monitoring disease status 3

Important Diagnostic Considerations

When evaluating for paraneoplastic SIADH, the diagnosis requires:

  • Hyponatremia (serum sodium < 134 mEq/L) 1, 6
  • Hypoosmolality (plasma osmolality < 275 mosm/kg) 1, 6
  • Inappropriately high urine osmolality (> 500 mosm/kg) 1, 6
  • Inappropriately high urinary sodium concentration (> 20 mEq/L) 1, 6
  • Absence of hypothyroidism, adrenal insufficiency, or volume depletion 1, 6

A serum uric acid level < 4 mg/dL in the presence of hyponatremia has a positive predictive value for SIADH of 73-100% 6, 7

Common Pitfall to Avoid

Do not overlook dual paraneoplastic syndromes in SCLC patients. SCLC can simultaneously produce both ADH and ACTH, causing both SIADH and ectopic Cushing syndrome 8, 9. The SIADH may be masked or underdiagnosed when ectopic ACTH syndrome is present, as cortisol and ADH have antagonistic effects on renal sodium excretion 9. Always evaluate for both syndromes when one is identified, as this affects prognosis and treatment planning 2, 8.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Paraneoplastic Syndromes in Lung Cancer

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Tolvaptan for SIADH in Myelodysplastic Syndrome with Blast Crisis.

WMJ : official publication of the State Medical Society of Wisconsin, 2015

Guideline

Management of Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH)

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

SIADH in Gastroenteritis

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.